Danica Palacio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Danica Palacio has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jacqueline T. Bork
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2 shared publications - John W. Baddley
Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore Maryland USA
2 shared publications - Poonam Mathur
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
2 shared publications - Aaron P. Rapoport
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
1 shared publication Anthony D. Harris
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA
1 shared publication- Ariel A. Fromowitz
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
1 shared publication
Latest Publications
- Open Access
Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells
Background. Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cell immunotherapy (CARTx) and subsequent T cell dysfunction increase risk for infection. However, it is difficult to discern infection from CRS in the early (up to Day 30) and late (Days 31–180) periods after CARTx due to overlapping signs and symptoms. Methods. We analyzed infectious complications and predictors of infection during the early and late periods after CARTx in 213 adult patients with malignancies over a 5-year period. Results. Overall, 75 patients (35%) had at least one infection, mostly within the first 30 days after CARTx. Infections occurring early after CARTx were mostly bacterial, whereas viral infections predominated after Day 30. In multivariate analyses, a high baseline CRP (≥5 mg/dL) was significantly associated with increased risk of infection in the early period after CARTx, and a Day-5-to-baseline-CRP ratio of <1.5 was significantly associated with a higher risk of infection through all 180 days after CARTx and during the late period after CARTx. Conclusions. Infections in adult patients are common up to 180 days after receiving CARTx. High baseline CRP without significant temporal changes may predict risk of infection. Tracking CRP trends may be a useful clinical tool for discerning causes of fever and guiding antibiotic stewardship in this population at high risk for infections.
Open AccessChanges in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells
Background. Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cell immunotherapy (CARTx) and subsequent T cell dysfunction increase risk for infection. However, it is difficult to discern infection from CRS in the early (up to Day 30) and late (Days 31–180) periods after CARTx due to overlapping signs and symptoms. Methods. We analyzed infectious complications and predictors of infection during the early and late periods after CARTx in 213 adult patients with malignancies over a 5-year period. Results. Overall, 75 patients (35%) had at least one infection, mostly within the first 30 days after CARTx. Infections occurring early after CARTx were mostly bacterial, whereas viral infections predominated after Day 30. In multivariate analyses, a high baseline CRP (≥5 mg/dL) was significantly associated with increased risk of infection in the early period after CARTx, and a Day-5-to-baseline-CRP ratio of <1.5 was significantly associated with a higher risk of infection through all 180 days after CARTx and during the late period after CARTx. Conclusions. Infections in adult patients are common up to 180 days after receiving CARTx. High baseline CRP without significant temporal changes may predict risk of infection. Tracking CRP trends may be a useful clinical tool for discerning causes of fever and guiding antibiotic stewardship in this population at high risk for infections.
- 27 December 2024
- Published by Springer Nature
- p. 143-153
Pulmonary Aspergillosis in Solid Organ Transplant
- 27 December 2024
- Published by Springer Nature
- p. 143-153
Pulmonary Aspergillosis in Solid Organ Transplant
- Open Access
- 7 August 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e137
Developing a diagnosis calculator to estimate the probability of bacterial pneumonia
Misdiagnosis of bacterial pneumonia increases risk of exposure to inappropriate antibiotics and adverse events. We developed a diagnosis calculator (https://calculator.testingwisely.com) to inform clinical diagnosis of community-acquired bacterial pneumonia using objective indicators, including incidence of disease, risk factors, and sensitivity and specificity of diagnostic tests, that were identified through literature review.
- 7 August 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e137
Open AccessDeveloping a diagnosis calculator to estimate the probability of bacterial pneumonia
Misdiagnosis of bacterial pneumonia increases risk of exposure to inappropriate antibiotics and adverse events. We developed a diagnosis calculator (https://calculator.testingwisely.com) to inform clinical diagnosis of community-acquired bacterial pneumonia using objective indicators, including incidence of disease, risk factors, and sensitivity and specificity of diagnostic tests, that were identified through literature review.
- Open Access
- 15 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (28) , e29750
Predictors of in-hospital mortality in a cohort of people living with HIV (PLHIV) admitted to an academic medical intensive care unit from 2009 to 2014: A retrospective cohort study
Outcomes for critically ill people living with human immunodeficiency virus (PLHIV) have changed with the use of antiretroviral therapy (ART). To identify these outcomes and correlates of mortality in a contemporary critically ill cohort in an urban academic medical center in Baltimore, a city with a high burden of HIV, we conducted a retrospective cohort study of individuals admitted to a medical intensive care unit (MICU) at a tertiary care center between 2009 and 2014. PLHIV who were at least 18 years of age with an index MICU admission of ≥24 hours during the 5-year study period were included in this analysis. Data were obtained for participants from the time of MICU admission until hospital discharge and up to 180 days after MICU admission. Logistic regression was used to identify independent predictors of hospital mortality. Between June 2009 and June 2014, 318 PLHIV admitted to the MICU met inclusion criteria. Eighty-six percent of the patients were non-Hispanic Blacks. Poorly controlled HIV was very common with 70.2% of patients having a CD4 cell count 3 within 3 months prior to admission and only 34% of patients having an undetectable HIV viral load. Hospital mortality for the cohort was 17%. In a univariate model, mortality did not differ by demographic variables, CD4 cell count, HIV viral load, or ART use. Regression analysis adjusted by relevant covariates revealed that MICU patients admitted from the hospital ward were 6.4 times more likely to die in hospital than those admitted from emergency department. Other positive predictors were a diagnosis of end-stage liver disease, cardiac arrest, ventilator-dependent respiratory failure, vasopressor requirement, non-Hodgkin lymphoma, and symptomatic cytomegalovirus disease. In conclusion, in this critically ill cohort with HIV infection, most predictors of mortality were not directly related to HIV and were similar to those for the general population.
- 15 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (28) , e29750
Open AccessPredictors of in-hospital mortality in a cohort of people living with HIV (PLHIV) admitted to an academic medical intensive care unit from 2009 to 2014: A retrospective cohort study
Outcomes for critically ill people living with human immunodeficiency virus (PLHIV) have changed with the use of antiretroviral therapy (ART). To identify these outcomes and correlates of mortality in a contemporary critically ill cohort in an urban academic medical center in Baltimore, a city with a high burden of HIV, we conducted a retrospective cohort study of individuals admitted to a medical intensive care unit (MICU) at a tertiary care center between 2009 and 2014. PLHIV who were at least 18 years of age with an index MICU admission of ≥24 hours during the 5-year study period were included in this analysis. Data were obtained for participants from the time of MICU admission until hospital discharge and up to 180 days after MICU admission. Logistic regression was used to identify independent predictors of hospital mortality. Between June 2009 and June 2014, 318 PLHIV admitted to the MICU met inclusion criteria. Eighty-six percent of the patients were non-Hispanic Blacks. Poorly controlled HIV was very common with 70.2% of patients having a CD4 cell count 3 within 3 months prior to admission and only 34% of patients having an undetectable HIV viral load. Hospital mortality for the cohort was 17%. In a univariate model, mortality did not differ by demographic variables, CD4 cell count, HIV viral load, or ART use. Regression analysis adjusted by relevant covariates revealed that MICU patients admitted from the hospital ward were 6.4 times more likely to die in hospital than those admitted from emergency department. Other positive predictors were a diagnosis of end-stage liver disease, cardiac arrest, ventilator-dependent respiratory failure, vasopressor requirement, non-Hodgkin lymphoma, and symptomatic cytomegalovirus disease. In conclusion, in this critically ill cohort with HIV infection, most predictors of mortality were not directly related to HIV and were similar to those for the general population.
- 1 July 2021
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 13 (3) , 100-110
Review of Intravesicular Cidofovir for BK Virus Hemorrhagic Cystitis
- 1 July 2021
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 13 (3) , 100-110
Review of Intravesicular Cidofovir for BK Virus Hemorrhagic Cystitis